Skip to main content

Newsroom press releases

15/12/23 - 17:38

Diasorin Board of Directors approves 2024-2027 Business Plan (294.02 KB)
Financial Data
Download

06/11/23 - 15:44

Diasorin and Gilead Sciences collaborate to develop a Fully Automated Diagnostic Assay for Hepatitis Delta Virus on Diasorin’s LIAISON XL® for the U.S. Market (506.97 KB)
Products Immunodiagnostic
Download

03/11/23 - 15:51

Third Quarter results confirm guidance for Fiscal Year 2023 (822.89 KB)
Financial Data
Download

24/10/23 - 15:03

Diasorin unveils its new Corporate identity and launches the new Group website: www.diasorin.com (574.08 KB)
Other
Download

27/07/23 - 14:27

Update 2023 Annual Calendar of Corporate Events (104.1 KB)
Other
Download

27/07/23 - 13:18

Revenues at constant perimeter of consolidation and ex-Covid up 5% at CER in Q2. FY 2023 Guidance Confirmed (598.06 KB)
Financial Data
Download

17/07/23 - 7:03

DiaSorin launches the LIAISON® Legionella Urinary Ag assay in all countries accepting the CE Mark to improve diagnosis of legionnaires’ disease (510.4 KB)
Products Immunodiagnostic
Download

03/07/23 - 11:48

Suspension of the effectiveness of the disqualifying accessory administrative sanction imposed by CONSOB to the Chief Executive Officer Mr. Carlo Rosa (102.52 KB)
Other
Download

13/06/23 - 15:18

DiaSorin launches the LIAISON® B·R·A·H·M·S MR-proADM™ assay in all countries accepting the CE Mark (578.05 KB)
Products Immunodiagnostic
Download

07/06/23 - 14:40

Communication of total amount of voting rights (7 June 2023) (141.14 KB)
Financial Disclosures
Download

05/06/23 - 21:58

Administrative sanctions imposed by CONSOB in connection with the alleged breach to disclose obligations relating to inside information. Action for annulment. (107.91 KB)
Other
Download

26/05/23 - 7:10

DIASORIN CONSOLIDATES STRATEGIC PARTNERSHIP WITH MEMED BY SIGNING AN AGREEMENT TO DISTRIBUTE MEMED BV® TEST FOR THE ITALIAN MARKET ON THE MEMED KEY® POINT-OF-NEED PLATFORM (159.38 KB)
Acquisition / Partnership
Download

09/05/23 - 11:56

Q1’23 REVENUES CONFIRM GUIDANCE FOR FISCAL YEAR 2023 (675.79 KB)
Financial Data
Download

28/04/23 - 12:52

Shareholders' Meeting 2023 (373.48 KB)
Other
Download

27/03/23 - 15:52

Update 2023 Annual Calendar of Corporate Events (483.89 KB)
Financial Disclosures
Download

27/03/23 - 14:38

Dividend coupon date correction (493.46 KB)
Financial Data
Download

27/03/23 - 13:35

REVENUE GROWTH, STRONG PROFITABILITY AND ROBUST CASH FLOW GENERATION IN 2022. PROPOSED ORDINARY DIVIDEND OF €1.10 PER SHARE (334.51 KB)
Financial Data
Download

17/03/23 - 22:05

DiaSorin Simplexa COVID Flu assay received U.S. FDA 510(K) clearance (155.02 KB)
Products Molecular
Download

28/02/23 - 16:06

Sale of Flow Cytometry and Imaging business from DiaSorin to Cytek® Biosciences completed (130.89 KB)
Acquisition / Partnership
Download

13/02/23 - 22:03

CYTEK BIOSCIENCES TO ACQUIRE FLOW CYTOMETRY AND IMAGING BUSINESS FROM DIASORIN (165.22 KB)
Acquisition / Partnership
Download

07/02/23 - 12:01

Update 2023 Annual Calendar of Corporate Events (288.3 KB)
Financial Disclosures
Download

08/11/13 - 1:00

The Board of Directors approves the Q3'13 Results (766.57 KB)
Financial Data
Download

29/10/13 - 1:00

DiaSorin signes a 5-year agreement with Roche (432.42 KB)
Acquisition / Partnership
Download

25/10/13 - 2:00

DiaSorin launches the EHEC Toxins test on stool samples (610.05 KB)
Products Immunodiagnostic
Download

10/10/13 - 2:00

DiaSorin launches the test for IgG to Trypanosoma Cruzi (Chagas) (615.28 KB)
Products Immunodiagnostic
Download

24/09/13 - 2:00

DiaSorin launches the hCG test on its LIAISON XL in the US (599.75 KB)
Products Immunodiagnostic
Download

01/08/13 - 2:00

The Board of Directors approves the results for the H1 '13 (386.67 KB)
Financial Data
Download

24/07/13 - 2:00

DiaSorin launches the new test for Toxoplasmosis on LIAISON IAM (490.89 KB)
Products
Download

11/07/13 - 2:00

DiaSorin obtains the approval of CLIA Hepatitis and Retrovirus tests in Brazil (113.84 KB)
Products Immunodiagnostic
Download

28/06/13 - 2:00

DiaSorin launches the test of Chlamydia Trachomatis IgG and IgA on LIAISON (78.13 KB)
Products Immunodiagnostic
Download

20/06/13 - 2:00

DiaSorin launches the new test for Parvovirus on LIAISON IAM (488.24 KB)
Products Immunodiagnostic
Download

10/05/13 - 2:00

The Board of Directors approves the results for Q1'13 (763.61 KB)
Financial Data
Download

02/05/13 - 2:00

Compensation Commitee-Errata corrige (179.38 KB)
Financial Data
Download

22/04/13 - 2:00

Shareholders' meeting approves FY Results 2012 (57.22 KB)
Financial Data
Download

17/04/13 - 2:00

FDA approves the Aldosterone assay (439.58 KB)
Products Immunodiagnostic
Download

02/04/13 - 2:00

DiaSorin signs an agreement with Seegene (243.64 KB)
Acquisition / Partnership
Download

08/03/13 - 1:00

The BoD approves FY 2012 results (477.24 KB)
Financial Data
Download

07/03/13 - 1:00

Notification of changes in share capital (46.86 KB)
Financial Data
Download

07/03/13 - 1:00

Notice availability By-Laws (36.87 KB)
Financial Data
Download

07/02/13 - 1:00

Clostridium difficile on LIAISON (available outside the US and Canada only) (79.83 KB)
Products Immunodiagnostic
Download

07/02/13 - 1:00

Notification of changes in share capital (46.89 KB)
Financial Data
Download

07/02/13 - 1:00

Notice availability By-Laws (139.13 KB)
Financial Data
Download

30/01/13 - 1:00

The Board of Directors approves the results for the FY '12 (477.24 KB)
Financial Data
Download

29/01/13 - 1:00

Aldosterone on LIAISON (available outside the US and Canada only) (76.47 KB)
Products Immunodiagnostic
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.